Coprococcus Eutactus Test · Stool

Your gut is home to trillions of bacteria, and only a small group of them actually produce the short-chain fat your intestinal lining feeds on. Coprococcus eutactus, often written as C. eutactus, is one of those producers, and research keeps turning up the same pattern: people with more of it tend to be healthier, and people with less of it tend to be sicker.

This test checks how much C. eutactus is showing up in a stool sample. It will not give you a diagnosis on its own. What it can do is tell you whether one of the most consistently studied beneficial gut bacteria is present in the kinds of amounts seen in healthy people, or whether your gut ecosystem is tilting in the direction observed in inflammatory bowel disease, depression, and metabolic dysfunction.

What C. eutactus Actually Does

C. eutactus lives in your colon, where it ferments fibers your own body cannot break down. One of its main products is butyrate, a short-chain fat that feeds the cells lining your gut, helps keep the intestinal barrier tight, and dampens the kind of low-grade inflammation that drives chronic disease.

Its favorite food is a fiber called beta-glucan, the same fiber found in oats and barley. Laboratory work on human gut bacteria shows that beta-glucan is a major growth substrate for C. eutactus and its close relatives. That matters because the fibers you eat (or do not eat) shape how much of this bacterium your gut can support.

Gut Inflammation and Crohn's Disease

The strongest human signal for C. eutactus is in inflammatory bowel disease. People with Crohn's disease consistently show depleted levels compared with healthy controls, and higher levels are linked to lower inflammatory markers in the blood. In a study of 435 people, diets high in inflammatory foods (refined sugar, processed meats, low fiber) tracked with lower C. eutactus, and that combination predicted both higher Crohn's risk and worse disease activity.

The same depletion pattern shows up across inflammatory bowel disease more broadly, including ulcerative colitis. A large analysis of 1,257 people linked reduced commensal gut bacteria (including C. eutactus) to elevated secondary bile acids and higher inflammation. Chronic constipation shows a similar fingerprint, with butyrate producers including Coprococcus running low.

Metabolic Health

Butyrate-producing bacteria from the broader Coprococcus genus (a related but slightly broader grouping than C. eutactus alone) have been repeatedly linked to better blood sugar control. In the MILES study of 388 adults, people with more butyrate producers had better insulin sensitivity and lower rates of dysglycemia (elevated or poorly controlled blood sugar).

In non-alcoholic fatty liver disease, a systematic review of human studies found that the Coprococcus genus is typically depleted, fitting a broader pattern where the loss of these anti-inflammatory bacteria accompanies metabolic disease. Whether C. eutactus specifically follows the exact same trajectory as the genus has not always been reported at species level, so read these genus-level findings as directionally relevant rather than identical.

Mood, Depression, and the Gut-Brain Axis

One of the largest microbiome studies of depression, covering 2,124 people, found that bacteria in the Coprococcus genus were consistently depleted in people with lower quality-of-life scores and higher depressive symptoms. A follow-up genome-wide study in 2,593 adults identified thirteen bacterial genera linked to depression, with Coprococcus among them.

The mechanism is thought to involve butyrate itself and the bacteria's ability to support the synthesis of neuroactive compounds like dopamine precursors. In rural Ugandan children, higher C. eutactus at 24 months predicted better language development at 36 months, with language-impaired children showing lower levels of anaerobic butyrate-producers including this species.

Immunity, Infection Outcomes, and Cancer Treatment

In 27 melanoma patients receiving immunotherapy, the presence of C. eutactus in stool was linked to longer progression-free survival. The finding is preliminary but fits a broader theme: a gut ecosystem rich in butyrate producers seems to support a better-regulated immune response.

A Mendelian randomization study (a genetic analysis method that helps separate cause from correlation) linked higher levels of Coprococcus2, a close relative of C. eutactus, to lower sepsis incidence and lower 28-day mortality. In atopic eczema, infants with more bacteria related to butyrate-producing C. eutactus had milder symptoms, and increases in these bacteria tracked with improvement over time.

Reference Ranges

No standardized clinical cutpoints exist for C. eutactus. This is a research and exploratory marker, and labs that report it typically compare your result against the distribution of a healthy reference population rather than against a diagnostic threshold. Results are usually categorized as detectable within the expected commensal range, below range, or above range relative to that lab's reference panel.

Because different labs use different sequencing methods and reference populations, the categories are not directly comparable between labs. Track your result within the same lab over time. The trend matters more than the absolute number, especially given how much this species can vary from sample to sample in the same person.

Why One Reading Is Not Enough

Gut microbiome readings can shift measurably within days in response to diet, stress, sleep, and medications. A single low reading could reflect a recent course of antibiotics, a week of travel eating, or a stool sample collected during acute illness. A single high reading can be equally misleading.

Get a baseline, then retest in 3 to 6 months if you are making dietary or supplement changes aimed at gut health. Once you have a trajectory, at least annual retesting is reasonable for ongoing monitoring. Pair repeated testing with a food diary for the week before each collection, because diet is one of the strongest short-term drivers of the result.

When Results Can Be Misleading

• Recent antibiotics: broad-spectrum antibiotics can wipe out butyrate-producing bacteria for weeks. Levels may take months to return to baseline, sometimes incompletely. If you finished antibiotics within 8 weeks of testing, your reading will likely underestimate your usual level.
• Chronic proton pump inhibitor use: PPIs (heartburn medications like omeprazole) reduce butyrate-producing Firmicutes and increase oral and pathogenic bacteria in the gut, shifting the entire community in ways that can lower C. eutactus.
• Very low-fiber eating in the days before collection: because C. eutactus feeds on fermentable fibers, a week of low fiber intake can reduce its abundance without any underlying disease.
• Acute illness or recent travel: gastrointestinal infections, stress, and sudden dietary changes during travel can temporarily depress beneficial bacteria. Wait 2 to 4 weeks after recovery for a representative reading.

What to Do With an Abnormal Result

A single low result is rarely actionable on its own. Look at it alongside stool calprotectin (an inflammation marker), pancreatic elastase (digestive capacity), and overall commensal abundance before drawing conclusions. A low C. eutactus paired with elevated calprotectin and reduced Faecalibacterium prausnitzii points toward an inflammatory pattern worth investigating with a gastroenterologist. A low reading with otherwise normal markers is more often a fiber, medication, or recent-illness story.

If you have ongoing digestive symptoms, an inflammatory bowel disease diagnosis, or are on long-term PPI or antibiotic therapy, your gastroenterologist is the right person to help interpret a comprehensive stool panel. If you are testing for preventive reasons, focus on the trend and on the dietary and medication factors that move this bacterium, rather than on a single number.